This study investigates the safety and efficacy of an investigational medication when used with chemotherapy in patients with metastatic pancreatic adenocarcinoma.
The study evaluates the combination treatment's overall safety and effectiveness. It focuses on understanding how well patients tolerate the treatment.
- Who can participate: Adults with metastatic pancreatic adenocarcinoma who have not received prior systemic treatment for their metastatic disease may participate. Participants must have a life expectancy of at least 3 months and meet specific health criteria.
- Study details: Participants will take an investigational medication along with chemotherapy drugs. Patients will continue treatment until disease progression or other criteria are met.